Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BY-NC 4.0The Korean Journal of Gastroenterology

The Role of Aeromonas Species as Enteropathogens in Patients with Inflammatory Bowel Disease

  • Daein Kim1
  • Jiyoung Yoon1
  • Jae-seok Kim2
  • You Sun Kim1
  1. 1Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
  2. 2Department of Laboratory, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
Read full textPDFDOICite

Abstract

Background/Aims: Aeromonas species are Gram-negative, flagellated bacilli suggested to be associated with inflammatory bowel disease (IBD) flare-ups, but their precise role remains controversial. This retrospective study investigated Aeromonas as an enteropathogen in patients with IBD.

Methods: This study analyzed patients who tested positive for Aeromonas via stool multiplex PCR at Kangdong Sacred Heart Hospital between June 2023 and May 2025.

Results: Among the overall IBD cohort, Aeromonas was detected in 11/94 patients (11.7%; five with ulcerative colitis and six with Crohn's disease), identifying it as the second most prevalent pathogen, closely following Clostridioides difficile (14.9%, 14/94). This positivity rate was significantly higher than the 3.6% (111/3,056) observed in patients without IBD (p<0.001). IBD patients showed significantly lower PCR cycle threshold values (34.68±4.5 vs. 39.24±4.5, p=0.004), indicating a higher abundance of genetic material.

Conclusions: In conclusion, Aeromonas positivity is significantly more prevalent in IBD patients and is associated with a higher abundance of genetic material and inflammatory markers. Nevertheless, it is unclear if Aeromonas, acting as an enteropathogen, directly triggers acute flare-ups or is merely a consequence of a pre-existing compromised mucosal environment in patients with IBD.

Related

  1. Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.
    Romain Altwegg, Miceli Corinne, Paul Carle +3
    Gastro hep advancesPeer-reviewedCC BYFull textGenetics & genomicsEurope PMC
  2. Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
    Alice Burgevin, Bénédicte Caron, Alexa Sasson +5
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full text10 citedGenetics & genomicsHAL
  3. Lack of Monitoring Is Associated with Risk of Acute Kidney Events among Patients with Inflammatory Bowel Disease
    Hamza Achit, Laurent Peyrin‐biroulet, Carole Ayav +2
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full text14 citedGenetics & genomicsHAL
  4. Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study.
    Marley Cutrona, Ahuva Cices, Marla C Dubinsky +1
    Crohn's & colitis 360Peer-reviewedCC BYFull textGenetics & genomicsEurope PMC
  5. Impact of inflammatory bowel disease on perioperative complications in patients undergoing hysterectomy.
    Haihua Liu, Lihui Chen, Nanfeng Huang +3
    BMC women's healthPeer-reviewedCC BY-NC-NDFull textGenetics & genomicsEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{kim2026role,
  title = {{The Role of Aeromonas Species as Enteropathogens in Patients with Inflammatory Bowel Disease}},
  author = {Daein Kim and Jiyoung Yoon and Jae-seok Kim and You Sun Kim},
  journal = {The Korean Journal of Gastroenterology},
  year = {2026},
  month = oct,
  doi = {10.4166/kjg.2027.027},
  url = {https://doi.org/10.4166/kjg.2027.027},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - The Role of Aeromonas Species as Enteropathogens in Patients with Inflammatory Bowel Disease
AU  - Daein Kim
AU  - Jiyoung Yoon
AU  - Jae-seok Kim
AU  - You Sun Kim
PY  - 2026
DA  - 2026/10/25
JO  - The Korean Journal of Gastroenterology
DO  - 10.4166/kjg.2027.027
UR  - https://doi.org/10.4166/kjg.2027.027
AB  - Background/Aims: Aeromonas species are Gram-negative, flagellated bacilli suggested to be associated with inflammatory bowel disease (IBD) flare-ups, but their precise role remains controversial. This retrospective study investigated Aeromonas as an enteropathogen in patients with IBD.  Methods: This study analyzed patients who tested positive for Aeromonas via stool multiplex PCR at Kangdong Sacred Heart Hospital between June 2023 and May 2025.  Results: Among the overall IBD cohort, Aeromonas was detected in 11/94 patients (11.7%; five with ulcerative colitis and six with Crohn's disease), identifying it as the second most prevalent pathogen, closely following Clostridioides difficile (14.9%, 14/94). This positivity rate was significantly higher than the 3.6% (111/3,056) observed in patients without IBD (p<0.001). IBD patients showed significantly lower PCR cycle threshold values (34.68±4.5 vs. 39.24±4.5, p=0.004), indicating a higher abundance of genetic material.  Conclusions: In conclusion, Aeromonas positivity is significantly more prevalent in IBD patients and is associated with a higher abundance of genetic material and inflammatory markers. Nevertheless, it is unclear if Aeromonas, acting as an enteropathogen, directly triggers acute flare-ups or is merely a consequence of a pre-existing compromised mucosal environment in patients with IBD.
SN  - 1598-9992
SN  - 2233-6869
ER  -